Human CD22/Luc Stable Cell Line - K562

CD22, also known as cluster of differentiation 22 or SIGLEC-2, is a transmembrane glycoprotein belonging to the sialic acid-binding immunoglobulin-like lectin family. It is predominantly expressed on the surface of mature B cells and plays a key regulatory role in B cell receptor signaling by modulating immune activation thresholds. The Human CD22/Luc Stable Cell Line - K562 is an engineered cell line derived from the K562 parental line, which originates from a human chronic myelogenous leukemia patient. These cells have been stably transduced to co-express full-length human CD22 on the cell surface along with a firefly luciferase reporter gene. The luciferase activity enables real-time bioluminescent detection, making these cells suitable for both in vitro and in vivo imaging applications.

This cell line serves as a versatile tool in immuno-oncology research, particularly for evaluating therapeutics targeting CD22. It is widely used in CAR-T cell cytotoxicity assays, where CD22-directed CAR-T cells are co-cultured with the target cells and killing efficiency is measured via luciferase-based readouts. The bioluminescent signal directly correlates with viable cell numbers, allowing for quantitative, high-throughput assessment of target cell lysis. Beyond CAR-T development, the line supports antibody-dependent cellular cytotoxicity (ADCC) assays, bispecific T cell engager (BiTE) evaluations, and antibody-drug conjugate (ADC) screening. Researchers also employ it for in vivo tumor xenograft models, where luciferase imaging permits non-invasive tracking of tumor burden and therapeutic response over time. Additionally, the cell line is useful for studying CD22 internalization dynamics, receptor-mediated signaling, and B cell biology in a controlled, non-B-cell context. Its stability, ease of culture, and compatibility with standard bioluminescence platforms make it a practical choice for both academic and industrial drug discovery programs.